Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis

Sergentanis, TN; Economopoulos, KP

dc.contributor.author	Sergentanis, TN	en
dc.contributor.author	Economopoulos, KP	en
dc.date.accessioned	2014-03-01T02:00:25Z
dc.date.available	2014-03-01T02:00:25Z
dc.date.issued	2010	en
dc.identifier.issn	0167-6806	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/29096
dc.subject	CYP1A1	en
dc.subject	Cytochrome P450	en
dc.subject	A2455G	en
dc.subject	Polymorphism	en
dc.subject	Breast cancer	en
dc.subject.classification	Oncology	en
dc.subject.other	ESTROGEN METABOLIC PATHWAY	en
dc.subject.other	AFRICAN-AMERICAN WOMEN	en
dc.subject.other	S-TRANSFERASE GENES	en
dc.subject.other	NORTH INDIAN WOMEN	en
dc.subject.other	POLYCHLORINATED-BIPHENYLS	en
dc.subject.other	LUNG-CANCER	en
dc.subject.other	WHITE WOMEN	en
dc.subject.other	P4501A1 POLYMORPHISM	en
dc.subject.other	GSTT1 POLYMORPHISMS	en
dc.subject.other	CIGARETTE-SMOKING	en
dc.title	Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2010	en
heal.abstract	Cytochrome P450s are enzymes which catalyze Phase-I metabolism reactions; cytochrome P450 1A1 (CYP1A1) is a member of the CYP1 family and participates in the metabolism of a vast number of xenobiotics, as well as endogenous substrates. Four single nucleotide polymorphisms in CYP1A1 have been studied concerning their potential implication in terms of breast cancer risk: T3801C, T3205C, A2455G (Ile462Val), and C2453A (Thr461Asp); controversy exists regarding their role. This meta-analysis aims to examine whether the four aforementioned polymorphisms are associated with breast cancer risk. Separate analyses were performed on Caucasian, Chinese, and African populations, as well as on premenopausal and postmenopausal women. Eligible articles were identified by a search of MEDLINE bibliographical database for the period up to October 2009. Concerning T3801C, 32 studies were eligible (11,909 cases and 16,179 controls), 29 studies (12,257 cases and 20,379 controls) were eligible for A2455G, 11 studies (7,189 cases and 8,491 controls) were eligible for C2453A, and eight studies were eligible for T3205C (1,378 cases and 1,642 controls). Pooled odds ratios (OR) were appropriately derived from fixed- or random-effect models. Sensitivity analysis excluding studies whose genotype frequencies in controls significantly deviated from Hardy-Weinberg equilibrium was performed. Homozygous subjects of Caucasian origin carrying the A2455G G allele exhibited elevated breast cancer risk (pooled OR = 2.185, 95% CI 1.253-3.808, fixed effects), whereas heterozygous carriers did not (pooled OR = 1.062, 95% CI 0.852-1.323, random effects). A2455G polymorphism status was not associated with breast cancer risk in Chinese subjects or specifically in premenopausal/postmenopausal women. T3801C, T3205C, and C2453A status were not associated with breast cancer risk at any analysis. In conclusion, this meta-analysis points to the A2455G G allele as a risk factor for breast cancer among Caucasian subjects. On the contrary, T3801C, T3205C, and C2453A status does not seem capable of modifying breast cancer risk.	en
heal.publisher	SPRINGER	en
heal.journalName	BREAST CANCER RESEARCH AND TREATMENT	en
dc.identifier.isi	ISI:000278810700015	en
dc.identifier.volume	122	en
dc.identifier.issue	2	en
dc.identifier.spage	459	en
dc.identifier.epage	469	en